Advertisement

Immunohistochemical Expression of ER, PR and HER2/neu in Endometrial Carcinoma

  • Kaustav Mohapatra
  • Sheela devi C. ShivalingaiahEmail author
Original Article
  • 37 Downloads

Abstract

Background

Endometrial carcinoma (EC) is the third common gynecologic cancer in India. It consists of two major histological types: the most common endometrioid or type I EC and non-endometrioid or type II EC. They are biologically distinct, and various markers have been proposed as prognostic biomarkers in EC besides clinical and pathological features.

Objectives

To study the immunohistochemical (IHC) expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2/neu) in EC and to correlate them with various clinicopathological parameters.

Methods

IHC study of ER, PR and HER2/neu was performed on 35 cases of histopathologically diagnosed EC in hysterectomy specimens for a period of 4 years from 2014 to 2017.

Results

Majority of the patients were aged 51–60 years, and the common comorbid conditions were type 2 diabetes mellitus, hypertension and obesity. Histologically, 31 (88.57%) cases were of type 1 EC and 4 (11.43%) were of type II EC; in type II EC, 2 (5.7%) cases were papillary serous carcinoma and the remaining two cases each were malignant mixed Mullerian tumor (MMMT) and dedifferentiated carcinoma (DC). ER expression was observed in 29 cases (82.9%) and was statistically significant with tumor stage, tumor grade, histological type and intraglandular necrosis. PR expression was seen in 22 (62.9%) cases and showed significant association with tumor grade, myometrial invasion and histological type. HER2/neu was expressed in one case.

Conclusion

Establishing the diagnosis of molecular subtype of EC with limited markers, namely ER/PR, HER2/neu expression similar to breast cancer, may be useful to determine the treatment and prognosis, especially in developing countries. Studies with larger sample sizes may elucidate their role, which was the limitation in this study.

Keywords

Endometrial cancer Immunohistochemistry ER/PR HER2/neu 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Zhang Y, Zhao D, Gong C, Zhang F, He J, Zhang W, et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta analysis. World J Surg Oncol. 2015;13:208–19.  https://doi.org/10.1186/s12957-015-0619-1.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T, et al. Expression of ER, PR, and Her-2/neu in endometrial cancer: aclinicopathological study. Asian Pac J Cancer Prev. 2010;11(1):215–20.PubMedGoogle Scholar
  3. 3.
    Maheshwari A, Kumar N, Mahantshetty U. Gynecological cancers: a summary of published Indian data. South Asian J Cancer. 2016;5(3):112–20.CrossRefGoogle Scholar
  4. 4.
    Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, et al. A HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009;100(1):89–95.CrossRefGoogle Scholar
  5. 5.
    Wilczyński M, Danielska J, Wilczyński J. An update of the classical Bokhman’s dualistic model of endometrial cancer. PrzMenopauzalny. 2016;15(2):63–8.Google Scholar
  6. 6.
    Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrialcancer. Lancet. 2016;387(10023):1094–108.CrossRefGoogle Scholar
  7. 7.
    Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device- delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125(1):263–70.CrossRefGoogle Scholar
  8. 8.
    Longacre TA, Broaddus R, Chuang LT, Cohen MB, Jarboe EA, Mutter GL, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the endometrium. Arch Pathol Lab Med. 2017;141(11):1508–12.CrossRefGoogle Scholar
  9. 9.
    Woo JS, Apple SK, Sullivan PS, Rao JY, Ostrzega N, Moatamed NA. Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience. Diagn Pathol. 2016;11(1):102.CrossRefGoogle Scholar
  10. 10.
    Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17(5):964–78.CrossRefGoogle Scholar
  11. 11.
    Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from national surgical adjuvant breast and bowel project protocol B-06. J Clin Oncol. 1988;6(7):1076–87.CrossRefGoogle Scholar
  12. 12.
    Kalogiannidis I, Petousis S, Bobos M, Margioula-Siarkou C, Topalidou M, Papanikolaou A, et al. HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma. Arch Gynecol Obstet. 2014;290(6):1231–7.CrossRefGoogle Scholar
  13. 13.
    Binder PS, Mutch DG. Update on prognostic markers for endometrial cancer. Womens Health. 2014;10(3):277–88.Google Scholar
  14. 14.
    Gehrig PA, Van Le L, Olatidoye B, Geradts J. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer. 1999;86(10):2083–9.CrossRefGoogle Scholar
  15. 15.
    Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A Phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92(3):744–51.CrossRefGoogle Scholar
  16. 16.
    Ellenson LH, Pirog EC. The female genital tract. In: Kumar V, Abbas AK, Aster JC (eds) Pathologic basis of disease, 9th edn. Philadelphia: Elsevier Saunders; pp 1014–18.CrossRefGoogle Scholar
  17. 17.
    Merritt MA, Strickler HD, Einstein MH, Yang HP, Sherman ME, Wentzensen N, et al. Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes Control. 2016;27(6):737–48.CrossRefGoogle Scholar
  18. 18.
    Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299–310.CrossRefGoogle Scholar
  19. 19.
    Lapińska-Szumczyk S, Supernat A, Majewska H, Gulczyński J, Luczak A, Biernat W, et al. HER2-positive endometrial cancer subtype carries poor prognosis. Clin Transl Sci. 2014;7(6):482–8.CrossRefGoogle Scholar
  20. 20.
    Tangen IL, Werner HM, Berg A, Halle MK, Kusonmano K, Trovik J, et al. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Eur J Cancer. 2014;50(17):3003–10.CrossRefGoogle Scholar
  21. 21.
    Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009;100(1):89–95.CrossRefGoogle Scholar
  22. 22.
    Ferrandina G, Ranelletti FO, Gallotta V, Martinelli E, Zannoni GF, Gessi M, et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER),and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol. 2005;98(3):383–9.CrossRefGoogle Scholar
  23. 23.
    Voss MA, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol. 2012;124(1):15–20.CrossRefGoogle Scholar
  24. 24.
    Al-Loh S, Al-Hussaini M. Undifferentiated endometrial carcinoma: a diagnosis frequently overlooked. Arch Pathol Lab Med. 2013;137(3):438–42.CrossRefGoogle Scholar
  25. 25.
    Mylonas I. Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Oncol Rep. 2010;24:385–93.CrossRefGoogle Scholar
  26. 26.
    Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, et al. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2013;130(3):463–9.CrossRefGoogle Scholar
  27. 27.
    Zannoni GF, Monterossi G, De Stefano I, Gargini A, Salerno MG, Farulla I, et al. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1(ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer. Hum Pathol. 2013;44(6):1047–54.CrossRefGoogle Scholar
  28. 28.
    Buza N, Roque MD, Santin AD. HER2/neu in endometrial cancer-a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med. 2014;138:343–50.CrossRefGoogle Scholar
  29. 29.
    Gul AE, Keser SH, Barisik NO, Kandemir NO, Cakir C, Sensu S, et al. The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. Diagn Pathol. 2010;5:13.CrossRefGoogle Scholar
  30. 30.
    Obeidat BR, Matalka II, Mohtaseb AA, Al-Kaisi NS. Selected immunohistochemicalmarkers in curettage specimens and their correlation with finalpathologic findings in endometrial cancer patients. Pathol Oncol Res. 2013;19(2):229–35.CrossRefGoogle Scholar
  31. 31.
    Suthipintawong C, Wejaranayang C, Vipupinyo C. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma. J Med Assoc Thai. 2008;91(12):1779–84.PubMedGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2019

Authors and Affiliations

  • Kaustav Mohapatra
    • 1
  • Sheela devi C. Shivalingaiah
    • 2
    Email author
  1. 1.VSSIMSARSambalpurIndia
  2. 2.JSS Medical CollegeMysoreIndia

Personalised recommendations